Researchers at Yale School of Medicine have identified a significant molecular difference in the brains of individuals with autism compared to their neurotypical peers. This discovery, published in The American Journal of Psychiatry, sheds light on the biological underpinnings of autism, a neurodevelopmental condition marked by challenges in social interaction, repetitive behaviors, and focused interests.
The study reveals that brains of autistic individuals exhibit a reduced number of specific receptors for glutamate, the brain’s primary excitatory neurotransmitter. This reduction may be linked to various characteristics associated with autism, according to the research team.
James McPartland, PhD, the study’s co-principal investigator and Harris Professor of Child Psychiatry and Psychology in the Child Study Center at Yale, emphasized the importance of this finding, stating, “We have found this really important, never-before-understood difference in autism that is meaningful, has implications for intervention, and can help us understand autism in a more concrete way than we ever have before.”
Neurons communicate using electrical signals and chemical messengers known as neurotransmitters. These interactions can either stimulate or inhibit neuronal activity. A well-balanced mix of excitatory and inhibitory signals is essential for proper brain function. The researchers suggest that an imbalance in these signals may contribute to the diverse traits observed in individuals with autism.
To investigate these differences, the team employed both magnetic resonance imaging (MRI) and positron emission tomography (PET) on 16 autistic adults and a control group of 16 neurotypical individuals. MRI provided anatomical insights, while PET revealed molecular functions within the brain.
David Matuskey, MD, co-principal investigator and associate professor of radiology and biomedical imaging at Yale, noted, “PET scans can help us pinpoint a molecular map of what’s going on in this glutamate system.” The results showed a lower availability of metabotropic glutamate receptor 5 (mGlu5) throughout the brains of autistic participants.
In addition, 15 of the autistic participants underwent an electroencephalogram (EEG) to measure electrical brain activity. The EEG findings correlated with the reduced mGlu5 receptors, suggesting potential clinical implications for understanding and treating autism.
While PET scans are valuable for brain studies, they are expensive and involve radiation exposure. The researchers propose that EEG could serve as a more accessible method to explore excitatory brain function further. Adam Naples, PhD, the study’s first author, stated, “EEG isn’t going to completely replace PET scans, but it might help us understand how these glutamate receptors might be contributing to the ongoing brain activity in a person.”
This research provides novel insights into the molecular differences between autistic individuals and neurotypical people. Currently, autism diagnosis relies heavily on behavioral observations, as the molecular aspects remain poorly understood. Clarifying the “molecular backbone” of autism could lead to improved diagnostic methods and support systems for those on the spectrum.
McPartland explained the potential impact of these findings: “Today, I go into a room and play with a child to diagnose autism. Now, we’ve found something that is meaningful, measurable, and different in the autistic brain.”
Despite the lack of medications aimed specifically at addressing the challenges faced by many with autism, the study’s findings could pave the way for new therapeutic approaches targeting the mGlu5 receptor. While many neurodivergent individuals thrive without treatment, innovative solutions could benefit those whose symptoms significantly affect their quality of life.
The study focused exclusively on autistic adults, leaving unanswered questions about whether the reduced receptor availability is a cause or a consequence of living with autism. Previous research utilizing PET scans has primarily included adults due to radiation concerns. Yet, Matuskey and his team are developing advanced techniques that may allow for lower radiation exposure.
Planned future studies aim to include children and adolescents, helping to establish a developmental narrative regarding the observed molecular differences. McPartland noted, “We want to start creating a developmental story and start understanding whether the things that we’re seeing are the root of autism or a neurological consequence of having had autism your whole life.”
The research team also seeks to investigate additional methods to apply PET technology, potentially including individuals with intellectual disabilities in their studies, broadening the understanding of autism’s complexities.
